What diseases can Nintedanib/Vigat mainly treat and who is it suitable for?

Nintedanib (Nintedanib) is a small molecule tyrosine kinase inhibitor with multi-target effects, trade name:Ofev. It is an innovative drug specially used to treat pulmonary fibrosisrelated diseases. It can effectively delay the progressive decline of lung function and is currently regarded as one of the important treatment options for patients with idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases.

Nintedanib reduces the abnormal proliferation of fibrotic cells and collagen deposition by blocking the signaling pathways of vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR), thereby slowing down the sclerosis process of lung tissue. According to the guidelines and FDA-approved indications, nintedanib is mainly used for three major categories of diseases:

The first is idiopathic pulmonary fibrosis (IPF), which is a chronic progressive lung disease with unknown cause and poor prognosis. Patients usually experience dyspnea, dry cough and continued decline in lung function. Nintedanib has been clinically proven to significantly reduce the rate of decline in vital capacity in patients with IPF, thereby delaying the progression of the disease. It is currently one of the global standard treatment drugs. Secondly, nintedanib is also approved for the treatment of chronic fibrotic interstitial lung diseases (ILDs) with progressive phenotypes. Such diseases usually include drug-induced pneumonia, chronic hypersensitivity pneumonitis, autoimmune-related lung diseases, etc. The development of the disease has similar fibrotic mechanisms. Third, nintedanib can be used for systemic sclerosis-related interstitial lung disease (SSc-ILD), which is a rare systemic autoimmune disease in which patients will gradually develop fibrosis of lung tissue due to connective tissue abnormalities, ultimately affecting respiratory function.

In terms of applicable population, nintedanib is mainly recommended for adult patients, especially patients diagnosed withIPF, SSc-ILD or other progressive fibrosing interstitial lung diseases. It is suitable for people with high disease activity, extensive pulmonary fibrosis shown on imaging, or continued decline in lung function.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib